Table 1.
Baseline characteristics
|
Patients tested for SARS-CoV-2 |
Patients who tested positive for SARS-CoV-2 |
||||
|---|---|---|---|---|---|
| No mental illness (n=164 540) | Any mental illness (n=51 878) | No mental illness (n=5717) | Any mental illness (n=1443) | ||
| Mean age, years (SD) | 46·2 (18·3) | 61·6 (19·2) | 44·8 (17·9) | 59·5 (17·2) | |
| Gender | |||||
| Men | 80 294 (48·8%) | 22 170 (42·7%) | 2297 (40·2%) | 572 (39·6%) | |
| Women | 84 246 (51·2%) | 29 708 (57·3%) | 3420 (59·8%) | 871 (60·4%) | |
| Region of residence | |||||
| Rural | 72 085 (43·8%) | 22 465 (43·3%) | 2789 (48·8%) | 646 (44·8%) | |
| Urban | 92 455 (56·2%) | 29 413 (56·7%) | 2928 (51·2%) | 797 (55·2%) | |
| History of diabetes | 21 048 (12·8%) | 17 312 (33·4%) | 556 (9·7%) | 394 (27·3%) | |
| History of cardiovascular disease | 16 610 (10·1%) | 16 218 (31·3%) | 282 (4·9%) | 223 (15·5%) | |
| History of cerebrovascular disease | 9343 (5·7%) | 12 783 (24·6%) | 219 (3·8%) | 239 (16·6%) | |
| History of COPD | 9682 (5·9%) | 8894 (17·1%) | 186 (3·3%) | 162 (11·2%) | |
| History of asthma | 19 135 (11·6%) | 13 333 (25·7%) | 483 (8·4%) | 231 (16·0%) | |
| History of hypertension | 38 406 (23·3%) | 27 832 (53·6%) | 1015 (17·8%) | 623 (43·2%) | |
| History of chronic kidney disease | 8701 (5·3%) | 6632 (12·8%) | 169 (3·0%) | 84 (5·8%) | |
| Charlson comorbidity index | |||||
| 0 | 104 118 (63·3%) | 13 100 (25·3%) | 4175 (73·0%) | 553 (38·3%) | |
| 1 | 17 882 (10·9%) | 7843 (15·1%) | 559 (9·8%) | 246 (17·0%) | |
| ≥2 | 42 540 (25·9%) | 30 935 (59·6%) | 983 (17·2%) | 644 (44·6%) | |
Data are n (%) unless specified. COPD=chronic obstructive pulmonary disease. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.